50 /100
MEDIUM RISK
Score updated Jul 13, 2026

ARQT — Arcutis Biotherapeutics, Inc. Dilution Risk Tracker

Track ARQT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ARQT — Get alerts when the score changes →

As of July 13, 2026, Arcutis Biotherapeutics, Inc. (ARQT) has a DilutionWatch DilutionScore of 50/100, rated MEDIUM dilution risk. Arcutis Biotherapeutics, Inc. has a market capitalization of $2.68B, 125.08M shares outstanding, 272 institutional holders tracked. Key dilution vectors include approximately 3 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
32
💰 Cash Runway
85
📊 Float Risk
25
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

Watch
Minor dilution signals detected
17%
💰 Capital Raise 35%
• Low cash runway: 3 months remaining
🔔 Track ARQT — Get forecast alerts →

💹 Market Data

Market Cap$2.68B
Shares Outstanding125.08M
Float92.59M
Cash$34.76M
Debt$109.42M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 18.6% shares (2026Q1 vs prior)
272 institutional holders · 156.41M shares
#1 MORGAN STANLEY 12.84M shares
#2 SUVRETTA CAPITAL MANAGEMENT, LLC 12.33M shares
#3 Frazier Life Sciences Management, L.P. 9.87M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest14.02M
Days to Cover6.3
% of Float15.1%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2020
4 INSIDER TRANSACTION Apr 03, 2026
4 INSIDER TRANSACTION Mar 04, 2026
4 INSIDER TRANSACTION Mar 04, 2026
4 INSIDER TRANSACTION Mar 03, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for ARQT Shareholders

Arcutis Biotherapeutics, Inc. (ARQT) has a DilutionScore of 50/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

Cash runway is a key watch item: ARQT has approximately 3 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for ARQT in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ARQT alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track ARQT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ARQT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for ARQT
📊 ARQT FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ARQT Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.